Santhera's Raxone® Receives First Positive EAMS Scientific Opinion from UK's MHRA in Duchenne Muscular Dystrophy - Seite 3

European Public Relations contact
Amber Fennell, Consilium Strategic Communications
Phone [phone]
[e-mail]

Disclaimer / Forward-looking statements
This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Santhera Pharmaceuticals Holding AG. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.

References
¹ Medicines and Healthcare products Regulatory Agency Patient safety and Marketing authorisations, variations and licensing guidance. Available at: https://www.gov.uk/guidance/apply-for-the-early-access-to-medicines-sc ... (June 2017)
² Public assessment report. Available at https://www.gov.uk/government/publications/early-access-to-medicines-s ...

# # #

News Release EAMS

---

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Santhera Pharmaceuticals Holding AG via Globenewswire

--- End of Message ---

Santhera Pharmaceuticals Holding AG
Hammerstrasse 49 Liestal Switzerland

ISIN: CH0027148649;